Current Report Filing (8-k)
01 July 2020 - 6:46AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): June 30, 2020
PROVENTION
BIO, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-38552
|
|
81-5245912
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
P.O.
Box 666, Oldwick, New Jersey 08858
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (908) 336-0360
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§
230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class
|
|
Trading
Symbol(s)
|
|
Name
of Each Exchanged on Which Registered
|
Common
Stock, $0.0001 par value per share
|
|
PRVB
|
|
The
Nasdaq Global Select Market
|
Item 8.01. Other Events.
On
June 30, 2020, Provention Bio, Inc. (the “Company”) issued a press release announcing that, due to the continuing
coronavirus (COVID-19) pandemic and out of concern for the health and safety of its stockholders and attendees at its 2020 Annual
Meeting of Stockholders (the “Annual Meeting”), the Company has changed the format of the Annual Meeting from in-person
to a virtual-only meeting format. As previously announced, the Annual Meeting will be held Wednesday, July 15, 2020, at 9:00 a.m.
Eastern Standard Time. Stockholders may attend the Annual Meeting only via remote communication as described in the press release,
a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits:
SIGNATURE
Pursuant
to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
Provention
Bio, Inc.
|
|
|
Date:
June 30, 2020
|
By:
|
/s/
Andrew Drechsler
|
|
|
Andrew
Drechsler
|
|
|
Chief
Financial Officer
|
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jun 2024 to Jul 2024
Provention Bio (NASDAQ:PRVB)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Provention Bio Inc (NASDAQ): 0 recent articles
More Provention Bio, Inc. News Articles